| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥79.3B | ¥72.6B | +9.3% |
| Operating Income | ¥42.5B | ¥39.7B | +7.0% |
| Ordinary Income | ¥42.6B | ¥39.9B | +6.7% |
| Net Income | ¥28.2B | ¥26.2B | +7.5% |
| ROE | 14.5% | 14.4% | - |
FY2026 Q3 results show Kitasato Corporation delivered revenue of 7.93B yen (YoY +9.3%), operating income of 4.25B yen (+7.0%), ordinary income of 4.26B yen (+6.7%), and net income of 2.82B yen (+7.5%). The company operates exclusively in medical equipment business as a single segment, achieving an exceptionally high operating margin of 53.5% and net profit margin of 35.5%. With total assets of 204.3B yen and equity of 194.3B yen, the company maintains a fortress balance sheet with cash holdings of 120.3B yen representing approximately 58.9% of total assets. ROE stands at 14.5%, supported primarily by superior profitability rather than asset efficiency or leverage. The quarterly performance demonstrates continued revenue and profit growth, reflecting the high value-added nature of the medical equipment business, though full-year guidance indicates expected operating income deceleration.
Revenue increased 6.68B yen or 9.3% YoY to 79.34B yen, driven by growth in the medical equipment business. Gross profit reached 52.64B yen with an exceptional gross margin of 66.3%, indicating strong pricing power and product differentiation in the medical equipment market. Operating income rose 2.78B yen or 7.0% to 42.48B yen, translating to an operating margin of 53.5%. The slower profit growth relative to revenue reflects selling, general and administrative expenses increasing from 9.21B yen to 10.16B yen (+10.3%), slightly outpacing revenue growth. Non-operating income contributed positively with foreign exchange gains of 0.48B yen and interest income of 0.14B yen, while interest expense remained minimal at 0.01B yen due to negligible debt. Ordinary income reached 42.58B yen (+6.7%), closely tracking operating income. The gap between ordinary income of 42.58B yen and net income of 28.17B yen represents a 33.9% effective tax rate, with income taxes of 14.41B yen. No extraordinary items such as impairment losses, restructuring charges, or asset sales were reported. This represents a revenue up, profit up pattern, with both top-line and bottom-line delivering growth, though profit growth moderated relative to revenue expansion due to SG&A expense increases.
The company operates as a single segment in medical equipment business, thus segment-level breakdown is not applicable. The entire business constitutes the core operation, generating the reported revenue of 79.34B yen and operating income of 42.48B yen with a 53.5% operating margin.
[Profitability] Operating margin of 53.5% represents exceptional profitability in the medical equipment sector, improving from 54.7% in the prior year with a slight compression of 1.2pt due to SG&A growth. Net profit margin of 35.5% (prior year 36.1%) reflects strong bottom-line conversion. ROE of 14.5% exceeds typical manufacturing sector returns, driven primarily by the 35.5% net margin multiplied by asset turnover of 0.388 and financial leverage of 1.05. The effective tax rate of 33.9% aligns with standard corporate taxation. [Cash Quality] Cash and deposits of 120.27B yen provide coverage of 12.8 times against short-term debt, indicating substantial liquidity cushion. Short-term investment securities of 15.74B yen further bolster liquid resources. [Investment Efficiency] Total asset turnover of 0.388 reflects capital-intensive operations with significant cash holdings. Accounts receivable turnover period of 56 days (calculated from 12.06B yen receivables) and inventory turnover of 62 days (from 4.53B yen inventory) yield a cash conversion cycle of approximately 316 days when combined with payables period of 198 days, indicating room for working capital optimization. [Financial Health] Equity ratio of 95.1% (194.26B yen equity against 204.33B yen assets) represents an exceptionally conservative capital structure. Current ratio of 1658.9% demonstrates overwhelming short-term solvency. Debt-to-equity ratio of 0.05 reflects minimal leverage with total liabilities of only 10.06B yen.
Cash and deposits increased 14.42B yen YoY to 120.27B yen, representing a 13.6% growth that exceeds revenue growth of 9.3% and suggests strong cash accumulation from operations. The improvement in cash position combined with net income growth of 7.5% to 28.17B yen indicates earnings are likely converting to cash, though detailed operating cash flow metrics are not available for this quarterly period. Working capital movements show accounts receivable of 12.06B yen against accounts payable of 24.29B yen, reflecting favorable supplier credit terms. Inventory of 4.53B yen increased from prior levels, contributing to the 62-day inventory turnover and extended cash conversion cycle of 316 days. The balance sheet reflects construction in progress of 7.11B yen, indicating ongoing capital investments for future growth capacity. Total assets increased 6.78B yen to 204.33B yen while equity grew 11.76B yen to 194.26B yen, with the difference absorbed by liability reduction, demonstrating disciplined capital allocation. The company maintains no significant interest-bearing debt, with short-term borrowings minimal and long-term debt absent. With current assets of 155.28B yen covering current liabilities of 9.36B yen by a factor of 16.6, liquidity position remains exceptionally robust to support dividend payments and strategic investments.
Ordinary income of 42.58B yen compared to operating income of 42.48B yen shows minimal non-operating contribution of 0.10B yen, representing just 0.1% of revenue. Non-operating income comprises primarily foreign exchange gains of 0.48B yen and interest income of 0.14B yen, partially offset by minor interest expenses of 0.01B yen and other non-operating expenses. The dominance of operating income in total profitability indicates high-quality, recurring earnings from core medical equipment operations. With an operating margin of 53.5% and effective tax rate of 33.9%, the path from revenue to net income follows a straightforward progression without significant non-recurring items. The absence of extraordinary gains, impairment charges, or restructuring expenses further confirms earnings quality. While detailed cash flow statements are unavailable for this quarterly report, the 13.6% increase in cash holdings exceeding both revenue growth of 9.3% and net income growth of 7.5% suggests positive operating cash generation. However, the extended cash conversion cycle of 316 days, driven by inventory holding period of 62 days and long payables cycle, warrants monitoring to ensure working capital efficiency does not deteriorate earnings quality through cash flow pressure.
Full-year guidance forecasts revenue of 106.02B yen, operating income of 53.74B yen, ordinary income of 52.67B yen, and net income of 34.98B yen. Q3 cumulative performance represents 74.8% of full-year revenue guidance, 79.1% of operating income guidance, and 80.5% of net income guidance. With Q3 typically representing 75% of annual progress, the company is tracking slightly ahead of standard progress on profitability metrics while slightly behind on revenue. The full-year forecast implies Q4 revenue of approximately 26.68B yen and operating income of 11.26B yen, representing lower quarterly performance than Q3's 24.38B yen revenue and 13.33B yen operating income run-rate, suggesting anticipated seasonal softness or conservative guidance. Year-over-year forecast changes show expected revenue growth of 2.9% but operating income decline of 7.1% and ordinary income decline of 8.7%, indicating margin compression concerns for the full year despite Q3's strong performance. The forecasted annual dividend of 41.0 yen per share translates to a projected payout ratio of 58.2% based on EPS guidance of 87.46 yen, reflecting a shareholder-friendly distribution policy.
Annual dividend is planned at 41.0 yen per share for the full fiscal year. Based on the forecasted net income of 34.98B yen and EPS of 87.46 yen, the dividend payout ratio is calculated at 46.9% (41.0/87.46). When measured against Q3 actual net income of 28.17B yen, the implied payout ratio rises to approximately 58.2% if the full dividend is paid. Prior period dividend information is not provided for year-over-year comparison. No share buyback programs were disclosed in the available data. The total return ratio equals the payout ratio of 46.9 to 58.2% as no buybacks are evident. The dividend policy reflects a relatively high payout orientation while maintaining adequate retained earnings for growth, supported by the company's substantial cash reserves of 120.27B yen providing ample coverage for dividend commitments.
First, regulatory and product quality risk presents material exposure as a single-segment medical equipment manufacturer. Any product recalls, quality issues, or changes in medical device regulations could impact the entire revenue base of 79.34B yen and the 53.5% operating margin. Given the medical equipment industry's stringent quality standards and evolving regulatory landscape, ongoing compliance costs and potential liability represent permanent operational risks. Second, working capital efficiency deterioration poses cash flow risk. The inventory turnover period of 62 days combined with a cash conversion cycle of 316 days indicates extended capital tied up in operations. If inventory turnover continues to slow or receivables collection deteriorates, the company's ability to generate operating cash flow relative to reported earnings could decline, potentially constraining dividend sustainability despite current high payout ratio of 58.2% and investment capacity represented by 7.11B yen in construction in progress. Third, earnings growth deceleration risk emerges from full-year guidance showing operating income decline of 7.1% YoY and ordinary income decline of 8.7% YoY, contrasting with Q3's positive growth. This implies anticipated margin compression in Q4 or conservative assumption setting, with SG&A expenses growing 10.3% potentially outpacing revenue growth if the forecasted 2.9% full-year revenue growth materializes. If cost control measures prove insufficient, the exceptionally high operating margin of 53.5% could face compression pressure affecting profitability sustainability.
[Industry Position] (Reference - Proprietary Analysis)
Profitability metrics demonstrate significant outperformance versus manufacturing sector medians. Operating margin of 53.5% substantially exceeds the industry median of 8.3% (IQR: 4.8 to 12.6%), placing the company in the top tier of operational efficiency. Net profit margin of 35.5% far surpasses the industry median of 6.3% (IQR: 3.2 to 9.0%), reflecting the high-value medical equipment business model. ROE of 14.5% outperforms the industry median of 5.0% (IQR: 2.9 to 8.1%), demonstrating superior capital returns. ROA of 13.8% (derived from net income to total assets) significantly exceeds the industry median of 3.3% (IQR: 1.8 to 5.2%).
Financial health indicators show mixed positioning. Equity ratio of 95.1% far exceeds the industry median of 63.8% (IQR: 49.5 to 74.7%), indicating exceptionally conservative leverage. Current ratio of 1658.9% dramatically surpasses the industry median of 2.84 (IQR: 2.10 to 3.81), reflecting substantial liquidity buffers. Financial leverage of 1.05 sits well below the industry median of 1.53 (IQR: 1.31 to 1.85), confirming minimal debt utilization.
Efficiency metrics reveal relative underperformance. Asset turnover of 0.388 trails the industry median of 0.58 (IQR: 0.42 to 0.66), reflecting heavy cash holdings reducing turnover efficiency. Inventory turnover of 62 days outperforms the industry median of 108.81 days (IQR: 49.60 to 154.77), suggesting relatively efficient inventory management. Receivables turnover of 56 days compares favorably to the industry median of 82.87 days (IQR: 68.43 to 115.00). However, payables turnover of 198 days significantly exceeds the industry median of 55.82 days (IQR: 41.74 to 89.89), indicating extended payment terms that benefit cash flow but may warrant supplier relationship monitoring.
Growth metrics show positive momentum. Revenue growth of 9.3% YoY exceeds the industry median of 2.7% (IQR: -1.9 to 7.9%), positioning the company among faster-growing manufacturers. The Rule of 40 metric (revenue growth plus operating margin) of 62.8% dramatically exceeds the industry median of 0.11 (IQR: 0.05 to 0.19), highlighting the company's exceptional combination of growth and profitability.
※ Industry: Manufacturing (N=98 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
Three key takeaways emerge from the earnings analysis. First, the company demonstrates exceptional profitability fundamentals with operating margin of 53.5% and net margin of 35.5% that are multiples of manufacturing industry medians, generating ROE of 14.5% that substantially exceeds peer performance. This profitability premium reflects sustainable competitive advantages in the medical equipment market, supported by gross margin of 66.3% indicating strong pricing power and product differentiation. The single-segment focus on medical equipment creates both concentration in a high-value market and dependency on this sector's performance.
Second, the balance sheet structure exhibits extreme financial conservatism with equity ratio of 95.1%, cash holdings of 120.27B yen representing 58.9% of total assets, and debt-to-equity ratio of 0.05. This fortress balance sheet provides substantial strategic flexibility for M&A, R&D investment, or shareholder returns, as evidenced by the planned 41.0 yen annual dividend representing 46.9 to 58.2% payout ratio. However, asset turnover of 0.388 trailing the industry median of 0.58 suggests opportunity cost from underutilized capital, with excess cash earning minimal returns compared to the high-margin core business.
Third, a disconnect emerges between Q3 momentum and full-year guidance that warrants attention. Q3 cumulative results show 9.3% revenue growth and 7.5% net income growth, yet full-year guidance projects 2.9% revenue growth with operating income declining 7.1% YoY. This implies anticipated Q4 weakness or conservative forecasting, with SG&A expense growth of 10.3% in Q3 potentially signaling margin pressure. Additionally, the extended cash conversion cycle of 316 days and inventory turnover period of 62 days indicate working capital efficiency deterioration that could constrain cash generation despite strong reported earnings. Monitoring operating cash flow conversion and working capital trends will be critical to assess whether the high dividend payout and growth investments remain sustainably funded by cash generation versus balance sheet drawdown.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.